Intramuscular Ketamine for Suicidal Ideation

This crossover, subject-blinded, clinical trial (n=0, withdrawn) aimed to correlate changes in brain activity with the reduction in suicidal ideation (SI) in response to a single intramuscular dose of ketamine.

Led by Principal Investigator Matthew Klein from the Icahn School of Medicine at Mount Sinai, the study intended to investigate ketamine’s anti-suicidal properties beyond its antidepressant effects. It will determine whether specific electroencephalogram (EEG) findings are associated with SI’s response to intramuscular ketamine and assess its effectiveness in treating acute SI.

The study commenced in February 2022 and concluded in March 2022, with no participants enrolled. The eligibility criteria include adults aged 18 to 70 with current clinically significant SI and inpatient status at the time of study initiation. Exclusion criteria encompass various conditions such as primary psychotic disorder, pregnancy, substance abuse, and medical issues requiring acute intervention.

The study employs a randomized, crossover design with participants receiving either intramuscular ketamine followed by placebo or vice versa. Primary outcome measures include changes in auditory mismatch negativity (EEG), while secondary outcome measures involve changes in the Montgomery-Asberg Depression Rating Scale (MADRS) #10 (SI).

Trial Details

The objective of the present research protocol, a cross-over, subject-blinded, clinical trial, is to correlate changes in brain activity with reduction in suicidal ideation in response to a single intramuscular dose of ketamine. While ketamine is increasingly used as a rapid, antidepressant agent, there is accumulating evidence of additional anti-suicidal properties that may be distinct from its effects on depression. This pilot study will be used to determine (1) whether specific electroencephalogram (EEG) findings are correlated with response of SI to intramuscular (IM) ketamine, and (2) the effectiveness of IM ketamine in the treatment of acute SI.

NCT Number NCT05105061

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.